Showing 2021-2030 of 3038 results for "".
- Novartis to Cut Over 2000 Jobs in Switzerland, UKhttps://modernod.com/news/novartis-to-cut-over-2000-jobs-in-switzerland-uk/2479850/Novartis announced that it will slash more than 2,000 jobs by 2022, including eliminating 1,700 positions in Switzerland and around 400 roles in the UK, as it looks to increase profitability. The move comes as the company consolidates manufacturing and shifts positions elsewhere as part of plans
- Cigna Now Covering Avedro’s FDA-Approved Cross-Linking Procedurehttps://modernod.com/news/cigna-now-covering-avedros-fda-approved-cross-linking-procedure/2479851/Avedro announced that 50 commercial insurance plans now cover Avedro’s FDA-approved corneal cross-linking procedure, following Cigna’s recent announcement that it is covering the Photrexa drug formulations and the KXL System used in the treatment of progressive keratoconus. Other health plans rec
- Bayer, Novartis Lose Case Seeking to End NHS Use of Avastin in Wet AMDhttps://modernod.com/news/bayer-novartis-lose-case-seeking-to-end-nhs-use-of-avastin-in-wet-amd/2479853/The UK High Court on Friday ruled that 12 NHS bodies in the north-east of England can continue to use Roche’s Avastin (bevacizumab) for the treatment of wet age-related macular degeneration (AMD) after dismissing a challenge by Bayer and Novartis. In the case, Bayer and Novartis, which mark
- Heidelberg Engineering OCT Angiography Module Now Available in the United Stateshttps://modernod.com/news/heidelberg-engineering-oct-angiography-module-now-available-in-the-united-states/2479879/Heidelberg Engineering announced that it has received FDA clearance for its OCT Angiography Module (OCTA). The additional module is now available for new and existing Spectralis upgradeable diagnostic imaging devices.
- Alcon Launches “Alcon Experience Academy” Online Portal for Training and Education for Eye Care Professionalshttps://modernod.com/news/alcon-launches-alcon-experience-academy-online-portal-for-training-and-education-for-eye-care-professionals/2479881/In an effort to provide face-to-face training and online educational resources, Alcon is launching a new online portal,
- Alcon Adds New Ultraviolet-Absorbing Only IOL Options to its AcrySof Portfoliohttps://modernod.com/news/alcon-adds-new-ultraviolet-absorbing-only-iol-options-to-its-acrysof-portfolio/2479895/Alcon expanded its AcrySof IOL portfolio with the introduction of multifocal and multifocal toric ultraviolet (UV)-absorbing IOLs, as well as the introduction of the AcrySof UV-Absorbing monofocal IOL with the UltraSert Preloaded Delivery System. “At Alcon, input from our surgeons is at th
- Clearside Biomedical to Present Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitishttps://modernod.com/news/clearside-biomedical-to-present-pivotal-phase-3-peachtree-clinical-trial-in-macular-edema-associated-with-non-infectious-uveitis/2479896/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana, MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreo
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-early-notification-of-fda-acceptance-of-nda-submission-for-roclatan/2479999/Aerie Pharmaceuticals reported that it has received the “Day 74” notification from the FDA earlier than scheduled. The FDA has completed its initial 60-day review of the new drug application (NDA) for Roclatan (netarsudil/latanoprostnetarsudil ophthalmic solution) 0.02%/0.005% and the FDA has det
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe